Supply Agreement Us
Following the release of the fifth tender on February 13, 2020, Gavi is pleased to announce a new agreement to supply conjugate pneumococcal vaccines (PCVs) under the Advance Market Commitment (AMC) and to introduce a new manufacturer to the AMC market at a reduced AMC tail price per dose. The following paragraphs are intended to provide specific information on the first agreements to supply the EX ante market obligation (AMC). The names of participating companies are listed in alphabetical order. Today`s premium, up to $1.525 billion, is for the manufacture and delivery of 100 million doses of RNA-1273, including incentive payments for timely delivery of the product. With the previous $955 million of BARDA for the development of RNA-1273 for licensing, today`s announcement brings the U.S. government`s commitments for early access to RNA-1273 to $2.48 billion. Under the agreement, the U.S. government, as part of Operation Warp Speed, will also be able to purchase up to 400 million doses of mNSA-1273 from Moderna. The U.S. government has announced that Americans, in accordance with their obligation to access COVID-19 vaccines free of charge, will receive RNA-1273 free of charge for the vaccine itself. As with government-purchased vaccines, health care professionals could charge the cost of administering the vaccine. The following paragraphs contain specific information about the assigned suppliers, the start date of delivery, the doses allocated and the amount of AMC funds that are not allocated.  The signing date is the first Monday of the week unicef signed the delivery agreements.  On March 17, 2016, GSK announced that it would lower the final price of its pneumococcal vaccine (PCV-10) to $3.05 per dose from 2017.  As soon as Pfizer`s third delivery contract comes into effect, cans purchased under these supply contracts will be purchased in 2013 for US$3.40 and US$3.30 as of 2014. On April 5, 2018, UNICEF, as gavi supply agency, confirmed a new delivery agreement with Pfizer Inc. Pfizer will provide 19 million doses per year (Annual Supply Commitment) per year for a 10-year period starting in 2018. As a result, 9.5% of AMC funds are allocated to this producer under this agreement, in accordance with the CMA`s terms and conditions. The price of the queue for this agreement is 2.95 $US for the presentation in 4 cans from 2018. The total doses allocated to Pfizer under its four procurement contracts amount to 930 million euros.